-
Centralized management of clinical trial feasibility requests: a single center database analysis from 2008 to 2015
Dorothee Arenz, Timo Siepmann and Oliver A Cornely
Research Paper: Clinical Investigation
-
Centralized management of clinical trial feasibility requests: a single center database analysis from 2008 to 2015
Dorothee Arenz, Timo Siepmann and Oliver A Cornely
Research Paper: Clinical Investigation
-
Centralized management of clinical trial feasibility requests: a single center database analysis from 2008 to 2015
Dorothee Arenz, Timo Siepmann and Oliver A Cornely
Research Paper: Clinical Investigation
-
Centralized management of clinical trial feasibility requests: a single center database analysis from 2008 to 2015
Dorothee Arenz, Timo Siepmann and Oliver A Cornely
Research Paper: Clinical Investigation
-
Centralized management of clinical trial feasibility requests: a single center database analysis from 2008 to 2015
Dorothee Arenz, Timo Siepmann and Oliver A Cornely
Research Paper: Clinical Investigation
-
Centralized management of clinical trial feasibility requests: a single center database analysis from 2008 to 2015
Dorothee Arenz, Timo Siepmann and Oliver A Cornely
Research Paper: Clinical Investigation
-
Centralized management of clinical trial feasibility requests: a single center database analysis from 2008 to 2015
Dorothee Arenz, Timo Siepmann and Oliver A Cornely
Research Paper: Clinical Investigation
-
Centralized management of clinical trial feasibility requests: a single center database analysis from 2008 to 2015
Dorothee Arenz, Timo Siepmann and Oliver A Cornely
Research Paper: Clinical Investigation
-
Application of biomarkers in oncology clinical trials
Naveen Dakappagari, Hua Gong, Reinhold Pollner, Amara Siva, Shabnam Tangri & Jelveh Lameh
Clinical Trail Methodology: Clinical Investigation
-
Application of biomarkers in oncology clinical trials
Naveen Dakappagari, Hua Gong, Reinhold Pollner, Amara Siva, Shabnam Tangri & Jelveh Lameh
Clinical Trail Methodology: Clinical Investigation
-
Application of biomarkers in oncology clinical trials
Naveen Dakappagari, Hua Gong, Reinhold Pollner, Amara Siva, Shabnam Tangri & Jelveh Lameh
Clinical Trail Methodology: Clinical Investigation
-
Application of biomarkers in oncology clinical trials
Naveen Dakappagari, Hua Gong, Reinhold Pollner, Amara Siva, Shabnam Tangri & Jelveh Lameh
Clinical Trail Methodology: Clinical Investigation
-
Application of biomarkers in oncology clinical trials
Naveen Dakappagari, Hua Gong, Reinhold Pollner, Amara Siva, Shabnam Tangri & Jelveh Lameh
Clinical Trail Methodology: Clinical Investigation
-
Application of biomarkers in oncology clinical trials
Naveen Dakappagari, Hua Gong, Reinhold Pollner, Amara Siva, Shabnam Tangri & Jelveh Lameh
Clinical Trail Methodology: Clinical Investigation
-
Application of biomarkers in oncology clinical trials
Naveen Dakappagari, Hua Gong, Reinhold Pollner, Amara Siva, Shabnam Tangri & Jelveh Lameh
Clinical Trail Methodology: Clinical Investigation
-
Application of biomarkers in oncology clinical trials
Naveen Dakappagari, Hua Gong, Reinhold Pollner, Amara Siva, Shabnam Tangri & Jelveh Lameh
Clinical Trail Methodology: Clinical Investigation
-
Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies
Jennifer C Cather, Elizabeth J Horn
Drug Evaluation: Clinical Investigation
-
Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies
Jennifer C Cather, Elizabeth J Horn
Drug Evaluation: Clinical Investigation
-
Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies
Jennifer C Cather, Elizabeth J Horn
Drug Evaluation: Clinical Investigation
-
Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies
Jennifer C Cather, Elizabeth J Horn
Drug Evaluation: Clinical Investigation
-
Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies
Jennifer C Cather, Elizabeth J Horn
Drug Evaluation: Clinical Investigation
-
Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies
Jennifer C Cather, Elizabeth J Horn
Drug Evaluation: Clinical Investigation
-
Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies
Jennifer C Cather, Elizabeth J Horn
Drug Evaluation: Clinical Investigation
-
Apremilast in the treatment of moderate-to-severe plaque psoriasis: results from the ESTEEM studies
Jennifer C Cather, Elizabeth J Horn
Drug Evaluation: Clinical Investigation
-
News: Amendment to UK Patent Act provides further exception to patent infringement
News and Views: Clinical Investigation
-
News: Amendment to UK Patent Act provides further exception to patent infringement
News and Views: Clinical Investigation
-
News: Amendment to UK Patent Act provides further exception to patent infringement
News and Views: Clinical Investigation
-
News: Amendment to UK Patent Act provides further exception to patent infringement
News and Views: Clinical Investigation
-
News: Amendment to UK Patent Act provides further exception to patent infringement
News and Views: Clinical Investigation
-
News: Amendment to UK Patent Act provides further exception to patent infringement
News and Views: Clinical Investigation
-
News: Amendment to UK Patent Act provides further exception to patent infringement
News and Views: Clinical Investigation
-
News: Amendment to UK Patent Act provides further exception to patent infringement
News and Views: Clinical Investigation
-
Can we improve the efficiency of early phase trials in pediatric oncology?
Esther Blanco & Darren Hargrave
Clinical Trail Perspective: Clinical Investigation
-
Can we improve the efficiency of early phase trials in pediatric oncology?
Esther Blanco & Darren Hargrave
Clinical Trail Perspective: Clinical Investigation
-
Can we improve the efficiency of early phase trials in pediatric oncology?
Esther Blanco & Darren Hargrave
Clinical Trail Perspective: Clinical Investigation
-
Can we improve the efficiency of early phase trials in pediatric oncology?
Esther Blanco & Darren Hargrave
Clinical Trail Perspective: Clinical Investigation
-
Can we improve the efficiency of early phase trials in pediatric oncology?
Esther Blanco & Darren Hargrave
Clinical Trail Perspective: Clinical Investigation
-
Can we improve the efficiency of early phase trials in pediatric oncology?
Esther Blanco & Darren Hargrave
Clinical Trail Perspective: Clinical Investigation
-
Can we improve the efficiency of early phase trials in pediatric oncology?
Esther Blanco & Darren Hargrave
Clinical Trail Perspective: Clinical Investigation
-
Can we improve the efficiency of early phase trials in pediatric oncology?
Esther Blanco & Darren Hargrave
Clinical Trail Perspective: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
Therapeutic targeting of tumor angiogenesis: how far have we come?
Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomes: Clinical Investigation
-
Therapeutic targeting of tumor angiogenesis: how far have we come?
Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomes: Clinical Investigation
-
Therapeutic targeting of tumor angiogenesis: how far have we come?
Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomes: Clinical Investigation
-
Therapeutic targeting of tumor angiogenesis: how far have we come?
Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomes: Clinical Investigation
-
Therapeutic targeting of tumor angiogenesis: how far have we come?
Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomes: Clinical Investigation
-
Therapeutic targeting of tumor angiogenesis: how far have we come?
Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomes: Clinical Investigation
-
Therapeutic targeting of tumor angiogenesis: how far have we come?
Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomes: Clinical Investigation
-
Therapeutic targeting of tumor angiogenesis: how far have we come?
Bruce C Baguley & Mark J McKeage
Clinical Trail Outcomes: Clinical Investigation
-
Comprehensive and effective system of standard operating procedures for investigator-initiated trials
Heike Moenkemann, Rita Pilger, Sylvia Reinecker, Peggy Houben & Ursula Paulu
Special Report: Clinical Investigation
-
Comprehensive and effective system of standard operating procedures for investigator-initiated trials
Heike Moenkemann, Rita Pilger, Sylvia Reinecker, Peggy Houben & Ursula Paulu
Special Report: Clinical Investigation
-
Comprehensive and effective system of standard operating procedures for investigator-initiated trials
Heike Moenkemann, Rita Pilger, Sylvia Reinecker, Peggy Houben & Ursula Paulu
Special Report: Clinical Investigation
-
Comprehensive and effective system of standard operating procedures for investigator-initiated trials
Heike Moenkemann, Rita Pilger, Sylvia Reinecker, Peggy Houben & Ursula Paulu
Special Report: Clinical Investigation
-
Comprehensive and effective system of standard operating procedures for investigator-initiated trials
Heike Moenkemann, Rita Pilger, Sylvia Reinecker, Peggy Houben & Ursula Paulu
Special Report: Clinical Investigation
-
Comprehensive and effective system of standard operating procedures for investigator-initiated trials
Heike Moenkemann, Rita Pilger, Sylvia Reinecker, Peggy Houben & Ursula Paulu
Special Report: Clinical Investigation
-
Comprehensive and effective system of standard operating procedures for investigator-initiated trials
Heike Moenkemann, Rita Pilger, Sylvia Reinecker, Peggy Houben & Ursula Paulu
Special Report: Clinical Investigation
-
Comprehensive and effective system of standard operating procedures for investigator-initiated trials
Heike Moenkemann, Rita Pilger, Sylvia Reinecker, Peggy Houben & Ursula Paulu
Special Report: Clinical Investigation
-
Designing better trials for epilepsy medications: the challenge of heterogeneity
Daniel Friedman, Jacqueline A French
Clinical Trail Methodology: Clinical Investigation
-
Designing better trials for epilepsy medications: the challenge of heterogeneity
Daniel Friedman, Jacqueline A French
Clinical Trail Methodology: Clinical Investigation
-
Designing better trials for epilepsy medications: the challenge of heterogeneity
Daniel Friedman, Jacqueline A French
Clinical Trail Methodology: Clinical Investigation
-
Designing better trials for epilepsy medications: the challenge of heterogeneity
Daniel Friedman, Jacqueline A French
Clinical Trail Methodology: Clinical Investigation
-
Designing better trials for epilepsy medications: the challenge of heterogeneity
Daniel Friedman, Jacqueline A French
Clinical Trail Methodology: Clinical Investigation
-
Designing better trials for epilepsy medications: the challenge of heterogeneity
Daniel Friedman, Jacqueline A French
Clinical Trail Methodology: Clinical Investigation
-
Designing better trials for epilepsy medications: the challenge of heterogeneity
Daniel Friedman, Jacqueline A French
Clinical Trail Methodology: Clinical Investigation
-
Designing better trials for epilepsy medications: the challenge of heterogeneity
Daniel Friedman, Jacqueline A French
Clinical Trail Methodology: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Long-term follow-up of human papillomavirus vaccine efficacy
Matti Lehtinen
Editorial: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 11
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 11
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 11
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 11
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 11
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 11
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 11
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 11
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 10
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 10
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 10
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 10
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 10
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 10
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 10
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2, Iss 10
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2: Iss 9
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2: Iss 9
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2: Iss 9
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2: Iss 9
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2: Iss 9
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2: Iss 9
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2: Iss 9
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation (2012) Vol 2: Iss 9
Acknowledgements: Clinical Investigation
-
Bioabsorbable stents-nothing from something
NS Rajendra, BJ Wrigley, AH Gershlick
Special Report: Clinical Investigation
-
Bioabsorbable stents-nothing from something
NS Rajendra, BJ Wrigley, AH Gershlick
Special Report: Clinical Investigation
-
Bioabsorbable stents-nothing from something
NS Rajendra, BJ Wrigley, AH Gershlick
Special Report: Clinical Investigation
-
Bioabsorbable stents-nothing from something
NS Rajendra, BJ Wrigley, AH Gershlick
Special Report: Clinical Investigation
-
Bioabsorbable stents-nothing from something
NS Rajendra, BJ Wrigley, AH Gershlick
Special Report: Clinical Investigation
-
Bioabsorbable stents-nothing from something
NS Rajendra, BJ Wrigley, AH Gershlick
Special Report: Clinical Investigation
-
Bioabsorbable stents-nothing from something
NS Rajendra, BJ Wrigley, AH Gershlick
Special Report: Clinical Investigation
-
Bioabsorbable stents-nothing from something
NS Rajendra, BJ Wrigley, AH Gershlick
Special Report: Clinical Investigation
-
An approach to personalized medicine: the BATTLE trial
Niels Reinmuth & Michael Thomas
Review Article: Clinical Investigation
-
An approach to personalized medicine: the BATTLE trial
Niels Reinmuth & Michael Thomas
Review Article: Clinical Investigation
-
An approach to personalized medicine: the BATTLE trial
Niels Reinmuth & Michael Thomas
Review Article: Clinical Investigation
-
An approach to personalized medicine: the BATTLE trial
Niels Reinmuth & Michael Thomas
Review Article: Clinical Investigation
-
An approach to personalized medicine: the BATTLE trial
Niels Reinmuth & Michael Thomas
Review Article: Clinical Investigation
-
An approach to personalized medicine: the BATTLE trial
Niels Reinmuth & Michael Thomas
Review Article: Clinical Investigation
-
An approach to personalized medicine: the BATTLE trial
Niels Reinmuth & Michael Thomas
Review Article: Clinical Investigation
-
An approach to personalized medicine: the BATTLE trial
Niels Reinmuth & Michael Thomas
Review Article: Clinical Investigation
-
Eltrombopag for the treatment of chronic immune thrombocytopenia
Stavroula Tsiara, Nichola Cooper
Review Article: Clinical Investigation
-
Eltrombopag for the treatment of chronic immune thrombocytopenia
Stavroula Tsiara, Nichola Cooper
Review Article: Clinical Investigation
-
Eltrombopag for the treatment of chronic immune thrombocytopenia
Stavroula Tsiara, Nichola Cooper
Review Article: Clinical Investigation
-
Eltrombopag for the treatment of chronic immune thrombocytopenia
Stavroula Tsiara, Nichola Cooper
Review Article: Clinical Investigation
-
Eltrombopag for the treatment of chronic immune thrombocytopenia
Stavroula Tsiara, Nichola Cooper
Review Article: Clinical Investigation
-
Eltrombopag for the treatment of chronic immune thrombocytopenia
Stavroula Tsiara, Nichola Cooper
Review Article: Clinical Investigation
-
Eltrombopag for the treatment of chronic immune thrombocytopenia
Stavroula Tsiara, Nichola Cooper
Review Article: Clinical Investigation
-
Eltrombopag for the treatment of chronic immune thrombocytopenia
Stavroula Tsiara, Nichola Cooper
Review Article: Clinical Investigation
-
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia
Brad Spellberg, Roger J Lewis, Helen W Boucher,Eric P Brass
Review Article: Clinical Investigation
-
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia
Brad Spellberg, Roger J Lewis, Helen W Boucher,Eric P Brass
Review Article: Clinical Investigation
-
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia
Brad Spellberg, Roger J Lewis, Helen W Boucher,Eric P Brass
Review Article: Clinical Investigation
-
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia
Brad Spellberg, Roger J Lewis, Helen W Boucher,Eric P Brass
Review Article: Clinical Investigation
-
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia
Brad Spellberg, Roger J Lewis, Helen W Boucher,Eric P Brass
Review Article: Clinical Investigation
-
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia
Brad Spellberg, Roger J Lewis, Helen W Boucher,Eric P Brass
Review Article: Clinical Investigation
-
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia
Brad Spellberg, Roger J Lewis, Helen W Boucher,Eric P Brass
Review Article: Clinical Investigation
-
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia
Brad Spellberg, Roger J Lewis, Helen W Boucher,Eric P Brass
Review Article: Clinical Investigation